Skip to content

Impact of Osteopathy on Pain After Breast Cancer Surgery

Study of the Impact of Osteopathic Care, Complementary Therapy to Standard Care, on Pain in Patients With Breast Cancer Surgery

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02621437
Acronym
IPOD
Enrollment
161
Registered
2015-12-03
Start date
2016-02-29
Completion date
2020-06-30
Last updated
2021-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

pain, quality of life, osteopathy, oncology, surgery, breast

Brief summary

Breast cancer can be painful following surgery or can develop later and remain persistent. Pain occurrence is frequent with 50% of women developing sequelae pain of varying intensity with an impact on the quality of life. One of the priorities of the 3rd French Cancer Plan is to preserve quality of life. Osteopathy, complementary therapy, may help to reduce inconvenience caused by the disease, treatments and their side effects (asthenia, anxiety and pain). The main objective is to assess the impact of osteopathic treatment on pain in patients following breast cancer surgery. The impact will be considered beneficial if the pain score (digital scale) in the intervention group is lower, by at least two points, than the pain score in the control group at the end of the study. This is a monocentric, randomized, parallel group, single-blind and prospective clinical trial.

Interventions

OTHEROsteopathy sessions

\- Three osteopathy sessions every 14 days (D13, D27 and D41 post-surgery),

OTHERphone questionnaires

Six phone questionnaires (D9, D20, D26, D34, D40 and D48): * pain questionnaire with digital scale, * quality of life survey: SF-12 * HAD (Hospital and Anxiety Depression) questionnaire

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult woman * Surgery for a malignant breast tumor with sentinel lymph node technique * Patient affiliated to a social security system * Willing and able to provide written informed consent

Exclusion criteria

* Under-age women * Pregnant woman * Surgery for a malignant breast tumor with lymph node dissection * Receiving adjuvant therapy during the study * Receiving physiotherapy sessions (other than those made in immediate post-operative) * Participating in the space Au Fil de Soi: relaxing body massage and Energy Resonance by Cutaneous Stimulation (RESC) * Person under guardianship or supervision * Patient with impaired cognitive functions or lack of understanding of the French language * Presenting a contraindication for osteopathy (major infectious and inflammatory conditions, trauma and other severe diseases)

Design outcomes

Primary

MeasureTime frameDescription
Assess the impact of osteopathic treatment on pain in patients following breast cancer surgeryat Day 9The primary outcome measure will be the evaluation of the usual pain in the last eight days measured from the pain score (digital scale). The pain score consists of asking the patient to quantify her pain on a virtual scale from 0 (absent pain) to 10 (worst pain imaginable).

Secondary

MeasureTime frameDescription
Assess the impact of osteopathic treatment on the quality of life in patients who have been operated on breast cancer.at day 9Assessment of quality of life by the SF-12 questionnaire, which is a shortened version of the Medical Outcomes Study Short-Form General Health Survey (SF-36), comprising only 12 of the 36 issues. The SF-12 is used to calculate two scores, which measure the functional health and well-being of the patient.
Assess the impact of osteopathic treatment on the reduction of anxiety of patients operated for breast cancer.at Day 9Assessment of anxiodepressive disorders from the HAD scale (Hospital and Anxiety Depression), each response is rated from 0-3 on a scale evaluating semi-quantitatively the intensity of symptoms during the past week. This study will use just the score of anxiety.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026